Protocols
|
June 8, 2023

A Functional Medicine IBS-D Protocol: Testing, Differential Diagnosis, and Treatment

Medically Reviewed by
Updated On
September 17, 2024

Irritable bowel syndrome (IBS) affects around 11% of the global population. In the United States, between 25 and 45 million people, typically females under age 50, have been diagnosed with IBS. The total annual cost of IBS in the US has been estimated at upwards of $10 billion in direct medical costs and an additional $19.2 billion in indirect costs. Despite these high numbers, less than half of IBS sufferers seek medical care; this means that many are left without the necessary medical support and are faced with dealing with the unpredictable and debilitating symptoms of IBS on their own. 

[signup]

What Is Irritable Bowel Syndrome With Diarrhea (IBS-D)?

IBS is a functional gastrointestinal disorder (FGID) characterized by chronic abdominal pain and disruptions in gastrointestinal (GI) function that cannot be explained by another diagnosis and lacks observable changes to GI anatomy. 

IBS-D, affecting about one-third of IBS sufferers, is one of three IBS subtypes in which the majority of abnormal movements patients experience are described as diarrhea. 

IBS-D Signs & Symptoms

Chronic abdominal pain and diarrhea are the hallmark symptoms of IBS-D. Diarrhea is defined as loose, watery, and frequent bowel movements.

It is common for patients with IBS-D to experience other GI symptoms, too, including: 

  • Gas
  • Abdominal bloating and distension
  • Indigestion
  • Nausea
  • Fecal urgency 

Root Causes of IBS-D

Although the exact cause of IBS-D is unclear, research points to abnormalities in gut motility, immune dysfunction, dysbiosis, and the central nervous system's misinterpretation of pain signals as contributing factors to digestive syndrome.

The microbiota-gut-brain axis has been highlighted as a central mechanism in the development and severity of IBS-D. This axis represents a bidirectional communication network linking the central nervous system, the enteric nervous system (the network of nerve cells that controls GI function), and the intestinal microbiome. Imbalances in this axis can trigger visceral hypersensitivity; in other words, the gut can become more sensitive than usual, creating abdominal pain sensations.

Dysbiosis characterized by altered composition and reduced diversity of gut microbes has been consistently observed in patients with IBS. This dysbiosis can affect gut motility, permeability, and inflammation, leading to the hallmark symptoms of diarrhea and abdominal pain. (34, 49)  

The gut microbiota also influences the production of neurotransmitters such as serotonin, which helps regulate gut motility and sensitivity. Dysregulation of serotonin pathways is commonly found in IBS-D, further linking gut microbial activity to symptom manifestation. 

The gut-brain axis involves significant neuroimmune interactions. Depression and anxiety, prevalent in the IBS community, can alter gut permeability and immune responses, exacerbating inflammation and dysbiosis (43). Conversely, gut microbiota can affect brain function and mood by producing metabolites that influence the central nervous system, creating a feedback loop that perpetuates the disorder (19). 

How to Diagnose IBS-D

Diagnosing IBS-D involves a comprehensive approach that thoroughly evaluates symptoms and medical history.

Step 1: Construct a Broad Differential Diagnosis

Recent medical guidelines dictate that IBS is no longer a diagnosis of exclusion. However, because IBS-D shares symptoms with many other conditions, healthcare practitioners should perform a comprehensive evaluation to rule out alternative causes of digestive symptoms before making an IBS diagnosis. These include, but are not limited to:

As such, the following list of labs is appropriate to order during an initial diagnostic evaluation to rule out common GI pathologies that can masquerade as IBS-D:

Step 2: Use the Rome IV Criteria 

The Rome IV criteria used for diagnosing IBS require that patients have recurrent abdominal pain at least one day per week during the previous three months that is associated with two or more of the following:

  • Defecation
  • A change in stool frequency
  • A change in stool appearance

IBS is subclassified as IBS with predominant diarrhea when a patient reports most of their abnormal bowel movements are diarrhea; specifically, more than 25% are loose or watery, and less than 25% are hard or lumpy (48).  

In 2021, the Rome Foundation proposed that IBS can be diagnosed if the patient's symptoms have lasted at least eight weeks and are bothersome (i.e., interfere with daily activities, cause worry, or interfere with quality of life).

Step 3: Use Specialty Labs to Uncover the Root Causes of IBS-D

The following labs are less commonly utilized in conventional medicine algorithms but can provide valuable insight into the possible triggers contributing to IBS. 

SIBO Breath Test

Up to 80% of IBS patients have SIBO (small intestinal bacterial overgrowth). A SIBO breath test measures various gas levels produced in the small intestine and exhaled through the breath. Elevations in hydrogen gas levels of at least 20 ppm by 90 minutes are diagnostic of hydrogen-predominant SIBO, most commonly associated with IBS-D. 

Order one of the following tests to screen for SIBO:

Comprehensive Stool Analysis

Research has linked IBS-D to bile acid diarrhea (BAD), exocrine pancreatic insufficiency (EPI), and small intestinal fungal overgrowth (SIFO). 

Common dysbiotic patterns characteristic of IBS-D include a reduced abundance of Lactobacillus and Bifidobacterium and an increased abundance of E. coli and Enterobacter. Patients with IBS are also more likely to have parasitic infections, specifically Blastocystis, Cryptosporidium, and Giardia. (9

A comprehensive stool analysis provides invaluable information regarding overall gut health. The following stool tests can detect pathogenic GI infections, fungal overgrowth, and other types of large intestinal dysbiosis. Fecal elastase and bile acids can be measured in stool samples to assess for EPI and BAD.

Food Sensitivity Testing

The majority (84%) of patients with IBS self-report food sensitivities as important triggers for their IBS symptoms. Food sensitivity panels can assist in the identification of dietary triggers so that dietary modifications can be better customized to the needs of each patient:

[signup]

Treatment Plan for IBS-D

Doctors can use a step-by-step approach to help patients palliate IBS symptoms while correcting the underlying imbalances leading to GI dysfunction.

Step 1: Palliate Symptoms

Here's Why This Is Important:

IBS, particularly IBS-D, significantly reduces health-related quality of life and work productivity due to GI symptoms.

How Do You Do This?

Treatment options for symptom relief include medications, dietary modifications, and gut-focused psychotherapy

The American Gastroenterological Association (AGA) recommends the following classes of medications for treating IBS-D:

  • Antidiarrheals: loperamide
  • Bile acid sequestrants: cholestyramine, colestipol
  • Antispasmodics: hyoscyamine, dicyclomine, peppermint oil
  • Antibiotics: rifaximin
  • Low-dose tricyclic antidepressants: amitriptyline, desipramine

Avoiding food sensitivities based on serum IgG antibodies can reduce IBS symptoms by 10-26%. Generally, elimination diets are recommended for 4-6 weeks, followed by a food rechallenge to confirm tolerance. 

If IgG antibody testing has yet to be performed, other dietary strategies, including low-FODMAP and gluten-free diets, have been shown to reduce and manage IBS symptoms effectively.

  • FODMAPs stands for fermentable oligosaccharides, disaccharides, monosaccharides, and polyols, which are difficult-to-digest carbohydrates. Restricting FODMAPs for 2-6 weeks has been shown to reduce pain and bloating, improve bowel habits, and improve quality of life in 75% of IBS patients. Monash University's app offers the most extensive FODMAP database, classifying foods as low, moderate, or high FODMAP with a simple traffic light system.
  • Long-term adherence to a gluten-free diet significantly reduces the severity of IBS symptoms and increases the likelihood of clinical remission. Grains to avoid on a gluten-free diet include barely (including malt), rye, and wheat (including kamut, semolina, spelt, and triticale).

Fiber generally helps relieve IBS symptoms by improving stool consistency, supporting the growth of beneficial commensals Lactobacillus and Bifidobacterium, and interacting with the nervous system to decrease pain signals. Most people do not meet the recommended minimum of 25 grams of dietary fiber daily. Non-fermentable fibers, such as psyllium, oats, and partially hydrolyzed guar gum, are usually best tolerated by those with IBS.

Step 2: Address the Microbiota-Gut-Brain Axis

Why Is This Important?

The bidirectional communication between the gut microbiota and the brain significantly influences gut and mental health, impacting symptoms such as inflammation, motility, and sensitivity. Targeting this axis increases the likelihood of long-term management without relying on medications and supplements.

How Do You Do This?

Antimicrobials may be needed to remove unwanted (bacterial, fungal, viral, and parasitic) microorganisms from the digestive tract. Herbal antimicrobial formulas are just as effective as the prescription antibiotic rifaximin in treating SIBO and, when used in combination with prescription antibiotics, can make therapy more effective and prevent antibiotic resistance. Common ingredients found in botanical antimicrobial formulas include:

  • Berberine
  • Oregano
  • Pau d'arco
  • Thyme
  • Allicin
  • Caprylic acid

Probiotics are live microorganisms that support the gut by balancing the microbiome. Two meta-analyses have shown Bifidobacterium and Lactobacillus probiotics to be safe and effective in treating IBS, likely by targeting the gut-brain axis to support digestion and mood self-regulation (57, 65).

Supplemental digestive enzymes provide enzymatic support when digestive enzyme insufficiency is present, contributing to malabsorption, malnutrition, food sensitivities, and gut inflammation. Patients with IBS taking digestive enzymes with meals report reduced IBS symptoms, including bloating, gas, and abdominal pain (50). Digestive enzyme formulas should be chosen based on a patient's lab findings and clinical symptoms and include one or more of the following:

  • Betaine hydrochloric acid
  • Pepsin
  • Amylases
  • Proteases
  • Lactase
  • Lipase
  • Ox bile

Aerobic exercise has been linked to the reduction of IBS symptoms. Possible mechanisms for this include improved mental health, the promotion of nerve growth through brain-derived neurotrophic factor, modulation of the hypothalamic-pituitary-adrenal (HPA) axis, and increasing diversity in the gut microbiome. 

The Risks of Untreated IBS-D

IBS does not permanently damage the intestines or increase the risk of serious diseases, such as cancer, or mortality

However, living with chronic IBS-D symptoms significantly reduces overall quality of life by limiting a person's participation in social events and work productivity. This leads to increased stress, anxiety, and depression, which can further exacerbate the condition and create a vicious cycle that impacts both physical and mental health.

IBS-D Case Study

To learn more about treating IBS, read this case study:

How One Patient Found Natural Relief For Her IBS

[signup]

Key Takeaways:

  • IBS-D is a chronic GI condition that causes mild to severe abdominal pain and diarrhea. 
  • Left untreated, IBS-D poses a significant risk to a person's quality of life. Unfortunately, conventional medications do not always manage IBS symptoms, leading people to seek alternative care options.
  • IBS can be difficult to diagnose and manage because many conditions have overlapping symptoms. By diving deeper, a comprehensive assessment can uncover the reasons behind GI imbalances that lead to IBS symptomology. A multifaceted strategy that recognizes the connection between the GI, immune, and nervous systems can profoundly transform the quality of life for those with IBS. 

Irritable bowel syndrome (IBS) affects around 11% of the global population. In the United States, between 25 and 45 million people, typically females under age 50, have been diagnosed with IBS. The total annual cost of IBS in the US has been estimated at upwards of $10 billion in direct medical costs and an additional $19.2 billion in indirect costs. Despite these high numbers, less than half of IBS sufferers seek medical care; this means that many are left without the necessary medical support and are faced with dealing with the unpredictable and challenging symptoms of IBS on their own. 

[signup]

What Is Irritable Bowel Syndrome With Diarrhea (IBS-D)?

IBS is a functional gastrointestinal disorder (FGID) characterized by chronic abdominal pain and disruptions in gastrointestinal (GI) function that cannot be explained by another diagnosis and lacks observable changes to GI anatomy. 

IBS-D, affecting about one-third of IBS sufferers, is one of three IBS subtypes in which the majority of abnormal movements patients experience are described as diarrhea. 

IBS-D Signs & Symptoms

Chronic abdominal pain and diarrhea are the hallmark symptoms of IBS-D. Diarrhea is defined as loose, watery, and frequent bowel movements.

It is common for patients with IBS-D to experience other GI symptoms, too, including: 

  • Gas
  • Abdominal bloating and distension
  • Indigestion
  • Nausea
  • Fecal urgency 

Root Causes of IBS-D

Although the exact cause of IBS-D is unclear, research suggests that abnormalities in gut motility, immune function, dysbiosis, and the central nervous system's interpretation of pain signals may contribute to digestive syndrome.

The microbiota-gut-brain axis has been highlighted as a central mechanism in the development and severity of IBS-D. This axis represents a bidirectional communication network linking the central nervous system, the enteric nervous system (the network of nerve cells that controls GI function), and the intestinal microbiome. Imbalances in this axis can trigger visceral hypersensitivity; in other words, the gut can become more sensitive than usual, creating abdominal pain sensations.

Dysbiosis characterized by altered composition and reduced diversity of gut microbes has been consistently observed in patients with IBS. This dysbiosis can affect gut motility, permeability, and inflammation, potentially leading to the hallmark symptoms of diarrhea and abdominal pain. (34, 49)  

The gut microbiota also influences the production of neurotransmitters such as serotonin, which helps regulate gut motility and sensitivity. Dysregulation of serotonin pathways is commonly found in IBS-D, further linking gut microbial activity to symptom manifestation. 

The gut-brain axis involves significant neuroimmune interactions. Depression and anxiety, prevalent in the IBS community, can alter gut permeability and immune responses, potentially exacerbating inflammation and dysbiosis (43). Conversely, gut microbiota can affect brain function and mood by producing metabolites that influence the central nervous system, creating a feedback loop that may perpetuate the disorder (19). 

How to Diagnose IBS-D

Diagnosing IBS-D involves a comprehensive approach that thoroughly evaluates symptoms and medical history.

Step 1: Construct a Broad Differential Diagnosis

Recent medical guidelines dictate that IBS is no longer a diagnosis of exclusion. However, because IBS-D shares symptoms with many other conditions, healthcare practitioners should perform a comprehensive evaluation to rule out alternative causes of digestive symptoms before making an IBS diagnosis. These include, but are not limited to:

As such, the following list of labs is appropriate to order during an initial diagnostic evaluation to rule out common GI pathologies that can masquerade as IBS-D:

Step 2: Use the Rome IV Criteria 

The Rome IV criteria used for diagnosing IBS require that patients have recurrent abdominal pain at least one day per week during the previous three months that is associated with two or more of the following:

  • Defecation
  • A change in stool frequency
  • A change in stool appearance

IBS is subclassified as IBS with predominant diarrhea when a patient reports most of their abnormal bowel movements are diarrhea; specifically, more than 25% are loose or watery, and less than 25% are hard or lumpy (48).  

In 2021, the Rome Foundation proposed that IBS can be diagnosed if the patient's symptoms have lasted at least eight weeks and are bothersome (i.e., interfere with daily activities, cause worry, or interfere with quality of life).

Step 3: Use Specialty Labs to Uncover the Root Causes of IBS-D

The following labs are less commonly utilized in conventional medicine algorithms but can provide valuable insight into the possible triggers contributing to IBS. 

SIBO Breath Test

Up to 80% of IBS patients have SIBO (small intestinal bacterial overgrowth). A SIBO breath test measures various gas levels produced in the small intestine and exhaled through the breath. Elevations in hydrogen gas levels of at least 20 ppm by 90 minutes are diagnostic of hydrogen-predominant SIBO, most commonly associated with IBS-D. 

Order one of the following tests to screen for SIBO:

Comprehensive Stool Analysis

Research has linked IBS-D to bile acid diarrhea (BAD), exocrine pancreatic insufficiency (EPI), and small intestinal fungal overgrowth (SIFO). 

Common dysbiotic patterns characteristic of IBS-D include a reduced abundance of Lactobacillus and Bifidobacterium and an increased abundance of E. coli and Enterobacter. Patients with IBS are also more likely to have parasitic infections, specifically Blastocystis, Cryptosporidium, and Giardia. (9

A comprehensive stool analysis provides invaluable information regarding overall gut health. The following stool tests can detect pathogenic GI infections, fungal overgrowth, and other types of large intestinal dysbiosis. Fecal elastase and bile acids can be measured in stool samples to assess for EPI and BAD.

Food Sensitivity Testing

The majority (84%) of patients with IBS self-report food sensitivities as important triggers for their IBS symptoms. Food sensitivity panels can assist in the identification of dietary triggers so that dietary modifications can be better customized to the needs of each patient:

[signup]

Treatment Plan for IBS-D

Doctors can use a step-by-step approach to help patients manage IBS symptoms while addressing the underlying factors contributing to GI function.

Step 1: Manage Symptoms

Here's Why This Is Important:

IBS, particularly IBS-D, significantly reduces health-related quality of life and work productivity due to GI symptoms.

How Do You Do This?

Treatment options for symptom relief include medications, dietary modifications, and gut-focused psychotherapy

The American Gastroenterological Association (AGA) recommends the following classes of medications for managing IBS-D:

  • Antidiarrheals: loperamide
  • Bile acid sequestrants: cholestyramine, colestipol
  • Antispasmodics: hyoscyamine, dicyclomine, peppermint oil
  • Antibiotics: rifaximin
  • Low-dose tricyclic antidepressants: amitriptyline, desipramine

Avoiding food sensitivities based on serum IgG antibodies can help reduce IBS symptoms by 10-26%. Generally, elimination diets are considered for 4-6 weeks, followed by a food rechallenge to confirm tolerance. 

If IgG antibody testing has yet to be performed, other dietary strategies, including low-FODMAP and gluten-free diets, have been shown to help manage IBS symptoms effectively.

  • FODMAPs stands for fermentable oligosaccharides, disaccharides, monosaccharides, and polyols, which are difficult-to-digest carbohydrates. Restricting FODMAPs for 2-6 weeks has been shown to help reduce pain and bloating, improve bowel habits, and improve quality of life in 75% of IBS patients. Monash University's app offers the most extensive FODMAP database, classifying foods as low, moderate, or high FODMAP with a simple traffic light system.
  • Long-term adherence to a gluten-free diet may help reduce the severity of IBS symptoms and increase the likelihood of clinical remission. Grains to avoid on a gluten-free diet include barely (including malt), rye, and wheat (including kamut, semolina, spelt, and triticale).

Fiber generally helps support digestive health by improving stool consistency, supporting the growth of beneficial commensals Lactobacillus and Bifidobacterium, and interacting with the nervous system to decrease pain signals. Most people do not meet the recommended minimum of 25 grams of dietary fiber daily. Non-fermentable fibers, such as psyllium, oats, and partially hydrolyzed guar gum, are usually best tolerated by those with IBS.

Step 2: Address the Microbiota-Gut-Brain Axis

Why Is This Important?

The bidirectional communication between the gut microbiota and the brain significantly influences gut and mental health, impacting symptoms such as inflammation, motility, and sensitivity. Targeting this axis may increase the likelihood of long-term management without relying on medications and supplements.

How Do You Do This?

Antimicrobials may be considered to help manage unwanted (bacterial, fungal, viral, and parasitic) microorganisms in the digestive tract. Herbal antimicrobial formulas may support digestive health and, when used in combination with prescription antibiotics, can make therapy more effective and help prevent antibiotic resistance. Common ingredients found in botanical antimicrobial formulas include:

  • Berberine
  • Oregano
  • Pau d'arco
  • Thyme
  • Allicin
  • Caprylic acid

Probiotics are live microorganisms that may support the gut by balancing the microbiome. Two meta-analyses have shown Bifidobacterium and Lactobacillus probiotics to be safe and effective in supporting digestive health, likely by targeting the gut-brain axis to support digestion and mood self-regulation (57, 65).

Supplemental digestive enzymes provide enzymatic support when digestive enzyme insufficiency is present, contributing to malabsorption, malnutrition, food sensitivities, and gut inflammation. Patients with IBS taking digestive enzymes with meals report reduced IBS symptoms, including bloating, gas, and abdominal pain (50). Digestive enzyme formulas should be chosen based on a patient's lab findings and clinical symptoms and include one or more of the following:

  • Betaine hydrochloric acid
  • Pepsin
  • Amylases
  • Proteases
  • Lactase
  • Lipase
  • Ox bile

Aerobic exercise has been linked to the reduction of IBS symptoms. Possible mechanisms for this include improved mental health, the promotion of nerve growth through brain-derived neurotrophic factor, modulation of the hypothalamic-pituitary-adrenal (HPA) axis, and increasing diversity in the gut microbiome. 

The Risks of Untreated IBS-D

IBS does not permanently damage the intestines or increase the risk of serious diseases, such as cancer, or mortality

However, living with chronic IBS-D symptoms significantly reduces overall quality of life by limiting a person's participation in social events and work productivity. This leads to increased stress, anxiety, and depression, which can further exacerbate the condition and create a vicious cycle that impacts both physical and mental health.

IBS-D Case Study

To learn more about managing IBS, read this case study:

How One Patient Found Natural Relief For Her IBS

[signup]

Key Takeaways:

  • IBS-D is a chronic GI condition that causes mild to severe abdominal pain and diarrhea. 
  • Left untreated, IBS-D poses a significant risk to a person's quality of life. Unfortunately, conventional medications do not always manage IBS symptoms, leading people to seek alternative care options.
  • IBS can be difficult to diagnose and manage because many conditions have overlapping symptoms. By diving deeper, a comprehensive assessment can uncover the reasons behind GI imbalances that lead to IBS symptomology. A multifaceted strategy that recognizes the connection between the GI, immune, and nervous systems can profoundly transform the quality of life for those with IBS. 
The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.

Learn more

No items found.

Lab Tests in This Article

  1. Atkinson, W. (2004). Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut, 53(10), 1459–1464. https://doi.org/10.1136/gut.2003.037697
  2. Aziz, I., Trott, N., Briggs, R., et al. (2016). Efficacy of a Gluten-Free Diet in Subjects With Irritable Bowel Syndrome-Diarrhea Unaware of Their HLA-DQ2/8 Genotype. Clinical Gastroenterology and Hepatology, 14(5), 696-703.e1. https://doi.org/10.1016/j.cgh.2015.12.031
  3. Ballou, S., & Keefer, L. (2016). The impact of irritable bowel syndrome on daily functioning: Characterizing and understanding daily consequences of IBS. Neurogastroenterology & Motility, 29(4), e12982. https://doi.org/10.1111/nmo.12982
  4. Böhn, L., Störsrud, S., Törnblom, H., et al. (2013). Self-Reported Food-Related Gastrointestinal Symptoms in IBS Are Common and Associated With More Severe Symptoms and Reduced Quality of Life. The American Journal of Gastroenterology, 108(5), 634–641. https://doi.org/10.1038/ajg.2013.105
  5. Brenner, D. M., Sayuk, G. S., Abel, J. L., et al. (2021). Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide. Journal of Managed Care & Specialty Pharmacy, 27(4), 469–477. https://doi.org/10.18553/jmcp.2021.27.4.469
  6. Card, T., Canavan, C., & West, J. (2014). The epidemiology of irritable bowel syndrome. Clinical Epidemiology, 6(6), 71–80. https://doi.org/10.2147/clep.s40245
  7. Chedid, V., Dhalla, S., Clarke, J. O., et al. (2014). Herbal Therapy is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth. Global Advances in Health and Medicine, 3(3), 16–24. https://doi.org/10.7453/gahmj.2014.019
  8. Chen, M., Ruan, G., Chen, L., et al. (2022). Neurotransmitter and Intestinal Interactions: Focus on the Microbiota-Gut-Brain Axis in Irritable Bowel Syndrome. Frontiers in Endocrinology, 13. https://doi.org/10.3389/fendo.2022.817100
  9. Cloyd, J. (2023, January 13). 6 Functional Medicine Labs That Can Help Diagnose The Root Cause of IBS-D. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-ibs-d-protocol
  10. Cloyd, J. (2023, February 28). How To Test for Lactose Intolerance. Rupa Health. https://www.rupahealth.com/post/how-to-test-for-lactose-intolerance
  11. Cloyd, J. (2023, March 6). 10 Differential Diagnosis for Your IBS Diarrhea (IBS-D) Patients. Rupa Health. https://www.rupahealth.com/post/10-differential-diagnosis-for-your-ibs-d-patients
  12. Cloyd, J. (2023, March 14). SIBO Testing 101: A Complete Guide to The Top 3 SIBO Tests. Rupa Health. https://www.rupahealth.com/post/sibo-testing-101-a-complete-guide-to-the-top-3-sibo-tests
  13. Cloyd, J. (2023, March 20). A Functional Medicine Approach to Treating Microscopic Colitis. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-approach-to-treating-microscopic-colitis
  14. Cloyd, J. (2023, March 29). An Integrative Medicine Guide to Ulcerative Colitis. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-guide-to-ulcerative-colitis
  15. Cloyd, J. (2023, March 30). An In-Depth Overview of the Three Types of SIBO: Hydrogen, Methane, Hydrogen Sulfide. Rupa Health. https://www.rupahealth.com/post/an-in-depth-overview-of-the-three-types-of-sibo-hydrogen-methane-hydrogen-sulfide
  16. Cloyd, J. (2023, April 20). Antibiotics 101: What You Need To Know. Rupa Health. https://www.rupahealth.com/post/antibiotics-101-what-you-need-to-know
  17. Cloyd, J. (2023, May 24). What are Digestive Enzymes: How to Test Your Patients Levels. Rupa Health. https://www.rupahealth.com/post/what-are-digestive-enzymes-how-to-test-your-patients-levels
  18. Cloyd, J. (2024, February 2). Navigating Dietary Management for IBS: A Functional Medicine Perspective. Rupa Health. https://www.rupahealth.com/post/navigating-dietary-management-for-ibs-a-functional-medicine-perspective
  19. Cloyd, K. (2023, December 5). The Gut-Brain Axis in Clinical Practice: Functional Approaches to Mental Wellness. Rupa Health. https://www.rupahealth.com/post/the-gut-brain-axis-in-clinical-practice-functional-approaches-to-mental-wellness
  20. Crowell, M. D. (2004). Role of serotonin in the pathophysiology of the irritable bowel syndrome. British Journal of Pharmacology, 141(8), 1285–1293. https://doi.org/10.1038/sj.bjp.0705762
  21. Dale, H. F., & Lied, G. A. (2020). Gut microbiota and therapeutic approaches for dysbiosis in irritable bowel syndrome: Recent developments and future perspectives. Turk J Med Sci, 50(7), 1632–1641. https://doi.org/10.3906/sag-2002-57
  22. Dalton, A., Mermier, C., & Zuhl, M. (2019). Exercise influence on the microbiome–gut–brain axis. Gut Microbes, 10(5), 1–14. https://doi.org/10.1080/19490976.2018.1562268
  23. Decesaris, L. (2022, August 30). How To Do An Elimination Diet. Rupa Health. https://www.rupahealth.com/post/how-to-do-an-elimination-diet
  24. Drossman, D. A., & Tack, J. (2021). Rome Foundation Clinical Diagnostic Criteria for Disorders of Gut-Brain Interaction (DGBI). Gastroenterology, 162(3), 675–679. https://doi.org/10.1053/j.gastro.2021.11.019
  25. El-Salhy, M., Ystad, S. O., Mazzawi, T., et al. (2017). Dietary fiber in irritable bowel syndrome (Review). International Journal of Molecular Medicine, 40(3), 607–613. https://doi.org/10.3892/ijmm.2017.3072
  26. Fibre supplements & IBS. (2019). Monash University. https://www.monashfodmap.com/blog/fibre-supplements-ibs/
  27. Fletcher, J. (2023, January 30). Is there a link between irritable bowel syndrome (IBS) and anxiety? Medical News Today. https://www.medicalnewstoday.com/articles/ibs-and-anxiety
  28. FODMAPs and Irritable Bowel Syndrome. Monash University. http://www.monashfodmap.com/about-fodmap-and-ibs/
  29. Get the App. Monash University. https://www.monashfodmap.com/ibs-central/i-have-ibs/get-the-app/
  30. Gluten-free diet. (2021, December 11). Mayo Clinic. https://www.mayoclinic.org/healthy-lifestyle/nutrition-and-healthy-eating/in-depth/gluten-free-diet/art-20048530
  31. Greenan, S. (2021, November 5). A Functional Medicine Approach To IBS. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-approach-to-ibs
  32. Greenan, S. (2021, November 18). How To Do A Low FODMAP Elimination Diet. Rupa Health. https://www.rupahealth.com/post/what-are-fodmaps
  33. Greenan, S. (2021, December 8). 5 Probiotic-Rich Foods To Eat Instead Of Taking Supplements. Rupa Health. https://www.rupahealth.com/post/the-different-types-of-probiotics-health-benefits
  34. Hrncir, T. (2022). Gut Microbiota Dysbiosis: Triggers, Consequences, Diagnostic and Therapeutic Options. Microorganisms, 10(3), 578. https://doi.org/10.3390/microorganisms10030578
  35. IBS Facts and Statistics. International Foundation for Gastrointestinal Disorders. https://aboutibs.org/what-is-ibs/facts-about-ibs/
  36. Irritable Bowel Syndrome Treatment. John Hopkins Medicine. https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/irritable-bowel-syndrome-treatment
  37. Khakham, C. (2023, May 23). A Comprehensive Review of IBS-D: Differential Diagnosis, Specialty Testing, and Integrative Treatment Options. Rupa Health. https://www.rupahealth.com/post/a-comprehensive-review-of-ibs-d-differential-diagnosis-specialty-testing-and-integrative-treatment-options
  38. Kresge, K. (2022, October 31). IBS vs IBD: Know the symptoms. Rupa Health. https://www.rupahealth.com/post/ibs-vs-ibd-know-the-symptoms
  39. Kresge, K. (2022, November 18). Pancreatic Exocrine Insufficiency: Symptoms, Diagnosis, & Treatment. Rupa Health. https://www.rupahealth.com/post/pancreatic-exocrine-insufficiency-symptoms-diagnosis-treatment
  40. Kresge, K. (2022, December 22). Functional Gastrointestinal Disorders: Diagnosis and Treatment. Rupa Health. https://www.rupahealth.com/post/what-are-functional-gastrointestinal-disorders-diagnosis-and-treatment
  41. Kurin, M., & Cooper, G. (2020). Irritable bowel syndrome with diarrhea: Treatment is a work in progress. Cleveland Clinic Journal of Medicine, 87(8), 501–511. https://doi.org/10.3949/ccjm.87a.19011
  42. Lehrer, J. K. (2024, May 15). Irritable Bowel Syndrome (IBS) Workup. Medscape. https://emedicine.medscape.com/article/180389-workup#c1
  43. Madison, A., & Kiecolt-Glaser, J. K. (2019). Stress, depression, diet, and the gut microbiota: human–bacteria interactions at the core of psychoneuroimmunology and nutrition. Current Opinion in Behavioral Sciences, 28(3), 105–110. https://doi.org/10.1016/j.cobeha.2019.01.011
  44. Mhanna, A., Martini, N., Hmaydoosh, G., et al. (2024). The correlation between gut microbiota and both neurotransmitters and mental disorders: A narrative review. Medicine, 103(5), e37114–e37114. https://doi.org/10.1097/md.0000000000037114
  45. Preston, J. (2023, June 21). An integrative medicine approach to food allergies: Specialty testing and treatment options. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-approach-to-food-allergies-specialty-testing-cross-contamination-and-treatment-options
  46. Psychological Treatments. International Foundation for Gastrointestinal Disorders. https://aboutibs.org/treatment/psychological-treatments/
  47. Reed, C. (2022, June 21). New AGA guidelines: A targeted approach to IBS-C and IBS-D treatment. American Gastroenterological Association. https://gastro.org/news/new-aga-guideline-a-targeted-approach-to-ibs-c-and-ibs-d-treatment/
  48. Rome IV Criteria. (2021, January 16). Rome Foundation. https://theromefoundation.org/rome-iv/rome-iv-criteria/
  49. Singh, R., Zogg, H., Wei, L., et al. (2020). Gut Microbial Dysbiosis in the Pathogenesis of Gastrointestinal Dysmotility and Metabolic Disorders. Journal of Neurogastroenterology and Motility, 27(1). https://doi.org/10.5056/jnm20149
  50. Spagnuolo, R., Cosco, C., Mancina, R. M., et al. (2017). Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome. European Review for Medical and Pharmacological Sciences, 21(2 Suppl), 102–107. https://pubmed.ncbi.nlm.nih.gov/28724171/
  51. Staller, K., Olén, O., Söderling, J., et al. (2020). Mortality Risk in Irritable Bowel Syndrome: Results From a Nationwide Prospective Cohort Study. The American Journal of Gastroenterology, 115(5), 746–755. https://doi.org/10.14309/ajg.0000000000000573
  52. Subtypes of IBS – Know the 3. (2022, April 1). International Foundation for Gastrointestinal Disorders. https://aboutibs.org/signs-and-symptoms/subtypes-of-ibs/
  53. Sun, Z., Wang, X., Feng, S., et al. (2023). A review of neuroendocrine immune system abnormalities in IBS based on the brain–gut axis and research progress of acupuncture intervention. Frontiers in Neuroscience, 17. https://doi.org/10.3389/fnins.2023.934341
  54. Sweetnich, J. (2023, March 9). Top Micronutrient Imbalances That Can Cause Diarrhea. Rupa Health. https://www.rupahealth.com/post/top-micronutrient-imbalances-that-can-cause-diarrhea
  55. Takakura, W., & Pimentel, M. (2020). Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome – An Update. Frontiers in Psychiatry, 11. https://doi.org/10.3389/fpsyt.2020.00664
  56. Tarar, Z. I., Farooq, U., Zafar, Y., et al. (2023). Burden of anxiety and depression among hospitalized patients with irritable bowel syndrome: a nationwide analysis. Ir J Med Sci, 192, 2159–2166. https://doi.org/10.1007/s11845-022-03258-6
  57. Tiequn, B., Guanqun, C., & Shuo, Z. (2015). Therapeutic Effects of Lactobacillus in Treating Irritable Bowel Syndrome: A Meta-analysis. Internal Medicine, 54(3), 243–249. https://doi.org/10.2169/internalmedicine.54.2710
  58. Vahedi, H., Ansari, R., Mir-Nasseri, M., et al. (2010). Irritable bowel syndrome: a review article. Middle East Journal of Digestive Diseases, 2(2), 66–77. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154827/
  59. Weinberg, J. L. (2022, February 28). An Integrative Medicine Approach to Celiac Disease. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-approach-to-celiac-disease
  60. Weinberg, J. L. (2022, April 14). Crohn's Disease Symptoms, Causes, And Treatment Options. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-approach-to-crohns-disease
  61. Weinberg, J. L. (2023, February 7). A Functional Medicine Protocol for Hyperthyroidism. Rupa Health. https://www.rupahealth.com/post/5-functional-medicine-labs-that-can-assist-a-root-cause-treatment-for-hyperthyroidism
  62. Weinberg, J. L. (2023, February 24). An Integrative Medicine Approach to SIFO: Small Intestinal Fungal Overgrowth. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-approach-to-sifo-small-intestinal-fungal-overgrowth
  63. Weinberg, J. L. (2023, April 17). Treating Bile Acid Diarrhea Naturally With The Help of Integrative Medicine. Rupa Health. https://www.rupahealth.com/post/treating-bile-acid-diarrhea-naturally-with-the-help-of-functional-medicine
  64. Wu, S., Yuan, C., Liu, S., et al. (2022). Irritable Bowel Syndrome and Long-Term Risk of Cancer: A Prospective Cohort Study Among 0.5 Million Adults in UK Biobank. American Journal of Gastroenterology, 117(5), 785–793. https://doi.org/10.14309/ajg.0000000000001674
  65. Yuan, F., Ni, H., Asche, C. V., et al. (2017). Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Current Medical Research and Opinion, 33(7), 1191–1197. https://doi.org/10.1080/03007995.2017.1292230
Order from 30+ labs in 20 seconds (DUTCH, Mosaic, Genova & More!)
We make ordering quick and painless — and best of all, it's free for practitioners.

Latest Articles

View more on Protocols
Subscribe to the magazine for expert-written articles straight to your inbox
Join the thousands of savvy readers who get root cause medicine articles written by doctors in their inbox every week!
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Trusted Source
Rupa Health
Medical Education Platform
Visit Source
Visit Source
American Cancer Society
Foundation for Cancer Research
Visit Source
Visit Source
National Library of Medicine
Government Authority
Visit Source
Visit Source
Journal of The American College of Radiology
Peer Reviewed Journal
Visit Source
Visit Source
National Cancer Institute
Government Authority
Visit Source
Visit Source
World Health Organization (WHO)
Government Authority
Visit Source
Visit Source
The Journal of Pediatrics
Peer Reviewed Journal
Visit Source
Visit Source
CDC
Government Authority
Visit Source
Visit Source
Office of Dietary Supplements
Government Authority
Visit Source
Visit Source
National Heart Lung and Blood Institute
Government Authority
Visit Source
Visit Source
National Institutes of Health
Government Authority
Visit Source
Visit Source
Clinical Infectious Diseases
Peer Reviewed Journal
Visit Source
Visit Source
Brain
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Rheumatology
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the National Cancer Institute (JNCI)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Cardiovascular Magnetic Resonance
Peer Reviewed Journal
Visit Source
Visit Source
Hepatology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Clinical Nutrition
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Bone and Joint Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Kidney International
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Allergy and Clinical Immunology
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Chest
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Neurology, Neurosurgery & Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Blood
Peer Reviewed Journal
Visit Source
Visit Source
Gastroenterology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Respiratory and Critical Care Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Diabetes Care
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of the American College of Cardiology (JACC)
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Clinical Oncology (JCO)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Clinical Investigation (JCI)
Peer Reviewed Journal
Visit Source
Visit Source
Circulation
Peer Reviewed Journal
Visit Source
Visit Source
JAMA Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
PLOS Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Nature Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The BMJ (British Medical Journal)
Peer Reviewed Journal
Visit Source
Visit Source
The Lancet
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the American Medical Association (JAMA)
Peer Reviewed Journal
Visit Source
Visit Source
Pubmed
Comprehensive biomedical database
Visit Source
Visit Source
Harvard
Educational/Medical Institution
Visit Source
Visit Source
Cleveland Clinic
Educational/Medical Institution
Visit Source
Visit Source
Mayo Clinic
Educational/Medical Institution
Visit Source
Visit Source
The New England Journal of Medicine (NEJM)
Peer Reviewed Journal
Visit Source
Visit Source
Johns Hopkins
Educational/Medical Institution
Visit Source
Visit Source

Hey practitioners! 👋 Join Dr. Chris Magryta and Dr. Erik Lundquist for a comprehensive 6-week course on evaluating functional medicine labs from two perspectives: adult and pediatric. In this course, you’ll explore the convergence of lab results across different diseases and age groups, understanding how human lab values vary on a continuum influenced by age, genetics, and time. Register Here! Register Here.

Hey practitioners! 👋 Join Dr. Terry Wahls for a 3-week bootcamp on integrating functional medicine into conventional practice, focusing on complex cases like Multiple Sclerosis. Learn to analyze labs through a functional lens, perform nutrition-focused physical exams, and develop personalized care strategies. Register Here.